E-therapeutics Share Discussion Threads

[george23666] 28/5/2020 21:26

You invested at 6p??? Wish I had! My investment came in at 16.8 and 17.9. Mind you, hopefully this will come in at 30p or more. Then decisions to make...

[harvey26311] 28/5/2020 21:20

I mean I wish I invested more at 6p. 👍

[george23666] 28/5/2020 21:13

DP, you are pretty clued up with the processes and share lingo if you don't mind me saying. So how do you think this will go tomorrow?
I have noticed that a few shares seem to load up after hours but not much comes to fruition. Mind you I have a very good feeling with ETX.

[george23666] 28/5/2020 21:09

Sorry Harvey, what do you mean by a negative?

[harvey26311] 28/5/2020 20:53

Wish we invested more at the lower levels.

[harvey26311] 28/5/2020 20:53

I know. Everyone must all have 1 negative with all this tho.....

[dplewis1] 28/5/2020 18:38

Crikey some monster trades come up after hours - surely get a TR-1 tomorrow or Monday

[jpuff] 28/5/2020 08:45

Covid is RNA based

[ali47fish] 28/5/2020 08:16

28 May 2020- good rns



e - t herapeutics plc



Expansion to encompass RNA interference (RNAi) as a new therapeutic modality and the formation of a Scientific Advisory Board (SAB)





Oxford, UK, 28th May 2020: e-therapeutics plc (AIM: ETX.L, "e-therapeutics" or "the Company") today announces its expansion into RNA interference (RNAi) as a therapeutic modality to pursue drug discovery outcomes and the creation of a Scientific Advisory Board headed by Dr Paul Burke.



e-therapeutics has a unique computational approach to drug discovery. Its Network-driven Drug Discovery (NDD) platform leverages its machine learning-enhanced database of over 15 million small molecule compounds to perform functional in silico phenotypic screens. In addition, its Genome-Associated Interactions Network (GAINs) proprietary platform enables the Company to distil actionable outcomes from complex genomic datasets. GAINs outputs are well suited to genetic medicine approaches as therapeutic interventions. As such, RNAi is an area that the Company plans to explore to harness computational drug discovery outcomes, both internally and in partnership with collaborators.



In addition, the Company has appointed Dr Paul Burke, Principal of Burke Bioventures LLC , as Chair of the Scientific Advisory Board (SAB). Dr Burke will work with the Company to appoint additional international advisors of the highest calibre to its newly formed SAB. Experience of SAB members will include genetics, computational approaches to drug discovery and deep drug development expertise, across small molecules and RNAi.



Dr Burke brings over two decades of biopharmaceutical industry experience across a broad range of therapeutic modalities. Paul was the founding head of Pfizer's global Center of Excellence for targeted drug delivery and imaging and Chief Technology Officer of its oligonucleotide therapeutics unit. Prior to that, he was Executive Director, RNA Therapeutics at Merck & Co. Paul previously built a decade-long career at Amgen, most recently serving as Executive Director, Pharmaceutics. Dr Burke received his BSc in Chemistry from Harvey Mudd College and his PhD in Biological Chemistry from MIT, and is currently Affiliate Professor of Bioengineering at the University of Washington .



Dr Paul Burke commented: " I am excited by the potential of e-therapeutics' platform technologies to critically inform the drug discovery process in a way that can generate not only novel small molecule candidates, but also those that are based on RNA, an important, emerging therapeutic modality. I look forward to working with the company to build a high calibre scientific advisory board that can provide meaningful insight and guidance to help them achieve their strategic and commercial goals."



Ali Mortazavi, Executive Chairman, said: "We are delighted to be working closely with Paul as we maximise the applicability of our computational technologies across therapeutic areas to transform the drug discovery process. RNAi is a key modality that is well suited to our business and in particular to translate our learnings from GAINs outcomes into targeted therapeutic strategies. Paul's expertise, together with that embedded in the organisation, positions the Company well to explore RNAi as part of our growth."

[jpuff] 28/5/2020 08:09

I think these tiny trades are mm to mm signals

[george23666] 28/5/2020 07:32

Yep, seen it. Very good. Why is there tiny trades in single digits DP?

[dplewis1] 28/5/2020 07:08

Nice RNS. There was even a 1 share trade yesterday which is obviously coincidence but will have people believing there's some kind of code..

[dplewis1] 27/5/2020 14:32

However nobody is selling.. there seems to be plenty of new money being attracted to ETX and not many people willing to part with their shares

[dplewis1] 27/5/2020 13:02

MMS caved finally

[dplewis1] 27/5/2020 10:01

Looks very much like it'll move up shortly. The 50k buy was an NT however there are a few MMs at 20.5 so may take a few more to shift them

[george23666] 27/5/2020 09:54

Loads of buys Dp..wondering why share price not climbing much?

[dplewis1] 27/5/2020 09:20

Plenty of buys going through today and late prints from yesterday as well

[george23666] 26/5/2020 21:19

Just messaged you Paul

[paulcon1] 26/5/2020 19:09

George

Ha Ha.... Wrong thread I know (found out earlier), am in the same boat with MWG, trying to get my head round why Great RNS's = No share price gain..

If you figure it out, please let me know.

GL

[george23666] 26/5/2020 17:38

I got suckered into MTFB unfortunately. Have interest in MWG and stuck with it and averaged out a couple of times. Has had a small flurry good RNS but levels out everytime which I need to get my head around.

[dplewis1] 26/5/2020 17:32

Small loss is better than a big loss! Not a fan of MTFB but CREO should have a good future. Into the NHS now and has some solid backers. Any company that makes products that reduces time in hospital has got to be worth a bet imo

[george23666] 26/5/2020 17:20

Dp - I got rid of motif and took a small loss btw

[george23666] 26/5/2020 17:18

Yep, I went on the back of contract to NHS which looks pretty good. Know I have come in late but hopefully some leverage left for upward movement?